Lifyorli (Copackaged) (relacorilant)
New molecular entity
- Region
- 🇺🇸 US
- Active substance
- relacorilant
- Company
- Corcept Therap
- Status
- Approved
- FDA approval
- Wed 25 Mar 2026
- Designations
- New molecular entity
- Application
- NDA220641
- Official record
- www.accessdata.fda.gov
Regulatory milestones
Wed 25 Mar 2026🇺🇸 FDA approval
FDA approves Lifyorli (Copackaged) (relacorilant), a new medicine
Corcept Therap; NDA220641; New molecular entity; capsule · source
Same substance in other markets
- 🇪🇺 Lifyorli Opinion · Corcept Therapeutics Netherlands B.V.
Follow Lifyorli (Copackaged)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.